TEL AVIV, Israel, March 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open. The Company will host a conference call on Thursday, March 23, 2017 at 9:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer, and David Malek, Chief Business Officer. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, http://www.biolinerx.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-281-1167 from the U.S. or +972-3-918-0687 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.biolinerx.com. A dial-in replay of the call will be available until March 26, 2017; please dial 1-888-782-4291 from the U.S. or +972-3-925-5940 internationally. About BioLineRx BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.